Brief: Vyloy (Zolbetuximab) Now Funded In Ontario And Quebec For Advanced Gastric Cancer
01/10/2025 14:55
Oct 1 (Reuters) - Astellas Pharma Inc 4503.T: VYLOY® (ZOLBETUXIMAB) IN COMBINATION WITH CHEMOTHERAPY FOR ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER IS NOW FUNDED IN BOTH ONTARIO AND QUEBEC Source text: ID:nCNWHy0pMa Further company coverage: 4503.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)